MoonLake Immunotherapeutics (MLTX)
割安ファンダメンタル
32
株価
$11.55
時価総額
$996M
パート1 · 企業の価値
概要
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
AbbVie's adalimumab (Humira) was the first biologic approved for hidradenitis suppurativa and still defines first-line treatment, while its risankizumab (Skyrizi) competes in psoriatic arthritis — both were used as active reference arms in MoonLake's own trials.
Lilly's ixekizumab (Taltz) is an IL-17A inhibitor prescribed for psoriatic arthritis, axial spondyloarthritis and plaque psoriasis, the rheumatology and dermatology indications sonelokimab is being developed for beyond hidradenitis suppurativa.
Incyte is bringing povorcitinib, an oral JAK1 inhibitor, through late-stage trials in hidradenitis suppurativa, competing for the same patients with a pill rather than an injection.
UCB's bimekizumab (Bimzelx) blocks the same IL-17A and IL-17F cytokines as sonelokimab and is already approved for hidradenitis suppurativa and psoriatic arthritis, the two indications MoonLake is bringing to market.
Novartis sells secukinumab (Cosentyx), the IL-17A inhibitor approved in 2023 for hidradenitis suppurativa and widely used in psoriatic arthritis and axial spondyloarthritis, addressing the same dermatology and rheumatology prescribers MoonLake targets.
貸借対照表と流動性
売上高
0
2025/12/31に終了した会計年度
純利益
$-227M
2025/12/31に終了した会計年度
フリーキャッシュフロー
$-196M
自己資本合計
$304M
負債合計
$120M
流動比率
12.56
利払い倍率
26.58
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
損益データがありません
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$28.54
現在株価
$11.55
安全マージン
+59.5%
適正価値レンジ
$27.11 - $29.97
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-74.7%
P/B レシオ
2.33
P/FCF
-
粗利益率
-
ROIC
-40.1%
収益性レーダー
価値創造（経済的モート）
ROIC
-40.1%
WACC
10.3%
ROIC − WACC
-50.4 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（7）
- P/B Ratio 2.33
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 77% Buy
- Share Dilution 2.3%
不合格（9）
- EPS shows upward trend
- Price CAGR 2.13%
- ROIC -40.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -82.7%
- Earnings Surprise avg -2.8%
- Piotroski F-Score 1/9
データなし（11）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 48 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 37 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | - |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | - |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | - |
| Joana Cortez | Associate Vice-President of Legal & Compliance | - |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | - |
| Luciana Marques | Associate Vice-President of HR, People and Culture | - |
| Ms. Nuala Brennan | Chief Clinical Development Officer | - |
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for MLTX, sourced from Markets Gazette.
- 3/30/2026POSITIVEMoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.
via Markets Gazette